Introduction
============

Chronic fatigue syndrome (CFS) is a common, debilitating illness whose hallmark symptoms involve fatigue and fatigability \[[@B1]-[@B5]\]. CFS has no diagnostic clinical signs or laboratory markers and is diagnosed based on self-reported symptoms and the ruling out of medical and psychiatric conditions that present similarly. There are several published definitions of CFS \[[@B1],[@B4],[@B5]\] that have proved useful in standardizing research subjects but lack empirical support \[[@B6],[@B7]\]. Several studies have described the heterogeneity of CFS \[[@B6],[@B8]-[@B11]\], but they recruited patients from clinical practices and relied on clinical and demographic information rather than physiological data. These studies have failed to identify consistent subgroups. Despite its prevalence and documented heterogeneity, systematic approaches to identify the endophenotypes comprising CFS have not been adopted.

We recently reported a more comprehensive approach to delineate the heterogeneity of medically unexplained chronic fatigue in 159 women from a population-based sample in Wichita, Kansas, USA \[[@B12],[@B13]\]. That study used principal components analysis to screen about 500 clinical, demographic, and laboratory measurements acquired from the 159 women during a two-day in-hospital case-control study and found that 38 variables accounted for the majority of the variance. Latent class analysis of these 38 variables identified four classes as the best fit model. Classes containing the most severely fatigued women were differentiated by sympathetic nervous system and endocrine activity, polysomnographic measures of sleep, mood disturbance, and multiplicity of symptoms. Women in Class 1 (32%) were unwell and obese with laboratory findings characteristic of metabolic strain. They had polysomnographic changes of hypnoea and were depressed and polysymptomatic. Women in Class 2 (28%) were obese but well. Those in Class 3 (26%) were unwell, polysymptomatic, and depressed, but had relatively normal body mass indices and normal biological markers. Finally, Class 4 (16%) comprised relatively well, non-obese women who were more symptomatic than Class 2.

We validated these latent classes against various independent measures, including severity, disability, gene expression profiles, and single nucleotide polymorphisms \[[@B13]-[@B15]\]. This is in accord with results from another study of 55 patients recruited from specialist care that has reported that quantitative gene expression analysis can differentiate seven CFS subgroups \[[@B16]\]. However, only gene expression was used to delineate the subgroups.

The objective of the current analysis was to replicate our previous comprehensive delineation approach with data collected during a survey of people from a different population, identified from metropolitan, urban, and rural populations of Georgia \[[@B17]\]. Although there were some differences in the measures used, we hypothesized that we would confirm the heterogeneity of medically unexplained chronic fatigue, and that the same measures would differentiate similar subgroups as those defined in the Wichita population-based study.

Methods
=======

This study adhered to human experimentation guidelines of the U.S. Department of Health and Human Services and the Helsinki Declaration. The CDC Institutional Review Board approved the study protocol. All participants were volunteers who gave informed consent.

Study participants
------------------

This study was part of a larger effort to evaluate the occurrence of, and risk factors for, CFS and unwellness in the 18- to 59-year-old population of the state of Georgia. Figure [1](#F1){ref-type="fig"} summarizes the sample, and details are available elsewhere \[[@B17]\]. Briefly, between September 2004 and July 2005, we used random digit dialing to conduct a household screening interview with a household informant in three Georgia populations (metropolitan, urban, and rural). A household informant described demographics and health status of household members ages 18 to 59. That initial interview enumerated 19,807 adult residents and screened for unwellness among household members for whom at least one CFS symptom was reported (fatigue, impaired cognition, un-refreshing sleep, muscle or joint pain). Well residents had none of these symptoms for ≥ one month. The screening interview identified 10,834 (55%) well people; 5,122 (26%) people who were unwell for at least a month but not fatigued; and 3,851 (19%) people who were unwell and fatigued for at least a month. We then conducted detailed telephone interviews with all those identified as unwell with fatigue, a random selection of those who were unwell but without fatigue, and a random sample of well people (see Figure [1](#F1){ref-type="fig"}). Based on their responses to the detailed telephone interview, we classified participants as CFS-like if they met criteria of the 1994 CFS case definition \[[@B5]\]; as chronically unwell if they exhibited some but not all CFS symptoms; and as well if they reported no such symptoms. Finally, we invited all 469 people classified as CFS-like; 641 well people (matched to the CFS-like people by sex, race/ethnicity, age, and geographic stratum); and a similar number (n = 505) of randomly selected unwell people for a one-day clinical evaluation. Overall, 48.5% completed the clinical evaluation.

![**Metropolitan, Urban, and Rural Georgia Study Populations**.](1478-7954-7-17-1){#F1}

Clinical evaluation and illness classification
----------------------------------------------

To identify medical conditions considered exclusionary for CFS \[[@B5],[@B7]\], the clinical evaluation included a standardized past medical history, a review of systems, a standardized physical examination, and routine laboratory testing of blood and urine \[[@B5],[@B7]\]. To identify psychiatric conditions considered exclusionary for CFS, licensed and specifically trained psychiatric interviewers administered the Structured Clinical Interview for DSM-IV (SCID) \[[@B18]\]. Exclusionary psychiatric disorders included current melancholic major depression, any psychotic condition, bipolar affective disorder, active substance abuse/dependence, anorexia or bulimia nervosa \[[@B5],[@B7]\]. Subjects with current non-melancholic major depressive episode or a past history of major depressive disorder were not excluded. The study identified exclusionary medical or psychiatric conditions in 280 (36%) of those evaluated clinically. They were excluded from further analyses, as were two others with incomplete data, leaving a total sample of 501 subjects.

We also diagnosed CFS based on the clinical evaluation according to criteria of the 1994 case definition \[[@B5]\] and as recommended by the International CFS Study Group \[[@B7]\], which is standard in CDC studies of CFS. Thus, we evaluated functional impairment by means of the Medical Outcomes Short-Form Health Survey (SF-36) \[[@B19]\]. We used the Multidimensional Fatigue Inventory (MFI-20) \[[@B20]\] to measure characteristics of fatigue, and we utilized the CDC CFS Symptom Inventory to document occurrence, frequency, and severity of the defining symptoms \[[@B21]\]. Subjects who had ≥ four case-defining symptoms, who exceeded the Symptom Inventory cut-off score, and who met CFS cut-off scores on the SF-36 and the MFI-20 were considered to have CFS (n = 113 participants). Those who met at least one, but not all CFS criteria, comprised the ISF group (n = 264), and those who met none of the cut-off criteria comprised the Well group (n = 124). In consideration of inadequate sample size for detecting the heterogeneity in both sexes, and for replication of the Wichita study (which only studied women), we opted to only study women. This left 386 women in the analysis for this paper.

Independent variables used to delineate the subgroups
-----------------------------------------------------

Although many of the 38 variables used in the Wichita study were the same (see Table [1](#T1){ref-type="table"}), some, such as nocturnal polysomnography, were not measured in the Georgia study. In all, 26 clinical and laboratory variables were the same or very similar to the 38 variables used in the Wichita study \[[@B13]\]. When a variable was not available, we used proxy measures to estimate the effect of the missing variable (see Table [1](#T1){ref-type="table"}). Cortisol index was the sum of four serum cortisol concentrations taken regularly over 24 hours minus the baseline concentration.

###### 

Defining variables used in the Wichita and Georgia studies

  **Wichita**                      **Georgia**
  -------------------------------- ----------------------------
  Unrefreshing sleep               Unrefreshing sleep
                                   
  Sleep problems                   Sleep problems
                                   
  Post-exertional fatigue          Post-exertional fatigue
                                   
  Muscle pain                      Muscle pain
                                   
  Joint pain                       Joint pain
                                   
  Severe headache                  Headache
                                   
  Concentration                    Concentration
                                   
  Photophobia                      Photophobia
                                   
  Sore throat                      Sore throat
                                   
  Shortness of breath              Shortness of breath
                                   
  Stomach or abdominal pain        Stomach or abdominal pain
                                   
  Fever                            Fever
                                   
  Nausea                           Nausea
                                   
  Depression (Zung score)          Depression (Zung score)
                                   
  Sleepiness (Epworth score)       Sleepiness (Epworth score)
                                   
  O~2~saturation                   
                                   
  Sleep resp. disturbance index    
                                   
  Sleep-total time                 
                                   
  Sleep-total arousals             
                                   
  Sleep-HR variability             Heart rate at rest
                                   
  Sleep REM latency                
                                   
  Age                              Age
                                   
  Body mass index                  Body mass index
                                   
  Neck circumference               Neck circumference
                                   
  High sensitivity CRP             High sensitivity CRP
                                   
  Serum insulin                    Serum insulin
                                   
  Free T3                          
                                   
  Progesterone                     
                                   
  Free testosterone                
                                   
  24 hours Urinary free cortisol   Cortisol index
                                   
  Hemoglobin                       Hemoglobin
                                   
  Bilirubin                        Bilirubin
                                   
  AST                              AST
                                   
  IL-6                             
                                   
  IL-1b                            
                                   
  Igf-1                            
                                   
  Tilt BP_5min_stand_index         Systolic blood pressure

Independent variables used to validate the subgroups
----------------------------------------------------

In order to externally validate the subgroups, we used the Short-Form Health Survey measure of functioning (SF-36) \[[@B19]\] and the Multidimensional Fatigue Inventory \[[@B20]\], neither of which had been used to define the classes.

Statistical analysis
--------------------

We used Latent GOLD^®^(LatentGOLD 4.1.3, Statistical Innovations, MA, USA) software to perform latent class analyses (LCA) on all variables and all subjects. Non-categorical variables were dichotomized by median split, and we filled missing (null) values (0.4% missing data values) with an intermediate categorical value. LCA is a statistical method for finding subtypes of similar subjects (latent classes) using multiple, defining, and categorical variables. LCA searches for an optimal class assignment for each subject so that most of the variation in the entire dataset can be explained by the subject\'s class assignment alone. LCA posits the existence of statistically uncorrelated measurements within each of the discovered classes. One therefore seeks measurements that most fully define the variability in the dataset, but are uncorrelated with each other. LCA and other clustering techniques seek to find loci in the multidimensional space of measurements (clinical and biological) where subjects cluster together. The subjects that are close to each other belong to the same class. Finding the locus for each class requires fitting one parameter for each dimension (measurement), and specifying a locus in an n-dimensional space requiring n parameters. To determine the optimal number of latent classes, we utilized the Akaike Information Criterion (with 3 as penalizing factor) (AIC3). AIC3 is defined by the following equation:

where *L*is the likelihood and *npar*is the number of estimated parameters.

Recent results \[[@B22],[@B23]\] suggest AIC3 is a better criterion than Bayesian or AIC for LCA models. We utilized AIC3 for the Wichita study and also utilize it here. The optimal number of classes is determined through locating a minimum in the value of AIC3 for solutions with different numbers of clusters. To validate the different classes, we compared independent variables across the empirically defined classes using Kruskal-Wallis or Mann-Whitney U tests for interval variables. Variables tested for validity included the Short-Form Health Survey (SF-36) and the Multidimensional Fatigue Inventory. A final test of validation was used to compare the empirically defined classes against a standardized application of impairment, fatigue, and symptom criteria of the 1994 CFS case definition \[[@B24]\] as recommended by the International CFS Study Group \[[@B7]\] and the screening criteria of \"unwell and not fatigued\" and \"well.\"

Results
=======

The AIC3 results for the four-, five-, and six-class solutions were respectively 13,856, 13,844, and 13,846. A five-class solution was statistically most significant, as the AIC3 was the lowest for this solution (13,844), and we therefore only show these data (four- and six-class solutions not shown).

Table [2](#T2){ref-type="table"} shows the five classes and associated data relating the variables that contributed significantly to the model as indicated by the Wald statistic. Class 1 (25%) captured ill subjects with many symptoms, prominent fatigue, sleep problems, and depression, but no aberrant biological markers (including body mass index) characterized this group. Class 2 (24%) similarly captured ill subjects who reported prominent, widespread symptoms, insomnia, and depression. However, these subjects had an associated metabolic syndrome (elevated insulin and inflammatory markers) and were obese. Class 3 (20%) included less ill subjects with fewer symptoms but similarly obese individuals with elevated serum insulin and inflammatory markers. Class 4 (20%) and Class 5 (11%) primarily included well individuals of normal weight. Class 5 included the youngest individuals and Class 4 the oldest.

###### 

Latent classes obtained from a five-class solution

  **Class Attributes**           **Class-1**   **Class-2**   **Class-3**   **Class-4**   **Class-5**   **Wald**   **p-Value**
  ------------------------------ ------------- ------------- ------------- ------------- ------------- ---------- -------------
  Number (%) of subjects         **97 (25)**   **92 (24)**   **77 (20)**   **76 (20)**   **44 (11)**              
                                                                                                                  
  Stomach problems (%)           **57**        **46**        **25**        **12**        **18**        **39.2**   **0.000**
                                                                                                                  
  Concentration difficulty       **33**        **53**        **5**         **0**         **0**         **29.1**   **0.000**
                                                                                                                  
  Fever                          **22**        **28**        **6**         **7**         **16**        **17.6**   **0.002**
                                                                                                                  
  Headache                       **84**        **79**        **53**        **46**        **77**        **33.8**   **0.000**
                                                                                                                  
  Joint pain                     **61**        **71**        **34**        **30**        **0**         **34.0**   **0.000**
                                                                                                                  
  Muscle pain                    **81**        **87**        **44**        **46**        **34**        **46.9**   **0.000**
                                                                                                                  
  Nausea                         **37**        **44**        **10**        **5**         **18**        **31.2**   **0.000**
                                                                                                                  
  Photophobia                    **44**        **63**        **14**        **8**         **0**         **51.6**   **0.000**
                                                                                                                  
  Shortness of breath            **22**        **47**        **8**         **0**         **4**         **32.0**   **0.000**
                                                                                                                  
  Sore throat                    **52**        **58**        **13**        **13**        **36**        **45.0**   **0.000**
                                                                                                                  
  Unusual fatigue                **70**        **86**        **32**        **8**         **11**        **89.6**   **0.000**
                                                                                                                  
  Unrefreshing sleep             **98**        **97**        **45**        **41**        **14**        **63.9**   **0.000**
                                                                                                                  
  Sleep problems                 **94**        **97**        **49**        **46**        **29**        **68.4**   **0.000**
                                                                                                                  
  Sleepiness (Epworth score)     **10**        **10**        **5**         **6**         **5**         **58.6**   **0.000**
                                                                                                                  
  Depression (Zung score)        **53**        **56**        **43**        **39**        **35**        **92.4**   **0.000**
                                                                                                                  
  Age (years)                    **42**        **44**        **48**        **51**        **38**        **37.6**   **0.000**
                                                                                                                  
  BMI (kg/m^2^)                  **24**        **32**        **32**        **24**        **22**        **85.6**   **0.000**
                                                                                                                  
  Neck circumference (cm)        **33**        **37**        **37**        **34**        **32**        **72.6**   **0.000**
                                                                                                                  
  High sensitivity CRP (mg/dL)   **0.10**      **0.42**      **0.51**      **0.1**       **0.08**      **72.4**   **0.000**
                                                                                                                  
  Serum insulin (units?)         **3.9**       **8.9**       **8.4**       **3.9**       **3.7**       **79.4**   **0.000**
                                                                                                                  
  Cortisol index                 **1.9**       **1.5**       **2.0**       **1.7**       **2.2**       **11.1**   **0.026**
                                                                                                                  
  Serum bilirubin                **0.4**       **0.4**       **0.4**       **0.5**       **0.4**       **14.5**   **0.006**
                                                                                                                  
  Serum AST                      **15**        **16**        **15**        **18**        **15**        **15.9**   **0.003**
                                                                                                                  
  Hemoglobin                     **13.0**      **13.4**      **13.1**      **13.3**      **12.6**      **20.6**   **0.000**
                                                                                                                  
  Heart rate (bpm)               **68**        **68**        **72**        **64**        **64**        **9.8**    **0.043**
                                                                                                                  
  Systolic blood pressure        **110**       **124**       **126**       **120**       **108**       **55.2**   **0.000**

Figures show (%) of total number in a class endorsing a symptom, median score on self-rating scales, or for biological markers, the median value for the respective class. The variables shown in the table are those significantly contributing to the class solution according to the Wald statistic. BMI = Body Mass Index. CRP = C reactive protein. AST = Aspartate transaminase.

As in the Wichita study, the four-class solution (data not shown) (AIC3 = 13,856) divided the sample along the dimension of obesity, resulting in two obese and two normal-weight classes. A secondary division on the basis of symptomatology shaped the final four classes such that Class 1 (27% of subjects) constituted a group of well subjects with normal BMI (median BMI = 23; median age = 45). Class 2 (25%) contained symptomatic and depressed subjects, with prominent sleep problems and normal BMI (median BMI = 24, median age = 42) but without abnormal biological markers. Class 3 subjects (25%) were obese (median BMI = 33; median age = 44), with the highest levels of symptoms, prominent depression, and poor sleep. In addition, these subjects had low cortisol levels and showed signs of obesity-associated metabolic strain, including higher levels of insulin and inflammatory markers. Class 4 (23%) consisted of obese older individuals (medium BMI = 31; median age = 48) with some sign of metabolic strain (e.g., raised insulin and inflammatory markers), but who were otherwise well.

Validation against independent variables not included in the model
------------------------------------------------------------------

The median values on the variables originally omitted from deriving optimal class solutions are shown for each of the five classes in Table [3](#T3){ref-type="table"}. With all five classes included in the analysis, nonparametric ANOVA produced highly significant overall tests indicative of substantial between-class differences for all variables (see Table [4](#T4){ref-type="table"}). We used Mann-Whitney U follow-up tests for fatigue and disability scores to compare each of the three ill classes against the two well classes (Classes 4 and 5). This confirmed significant differences across all the dimensions of disability and fatigue between Classes 1 and 2 and the well Classes 4 and 5 (all *P*values \< 0.001). Comparisons among the less symptomatic but still ill Class 3 and both of the well classes still produced highly significant differences for physical functioning, and for general, physical, and mental fatigue (all *P*values \< 0.008). Similarly, there were significant differences in activity and motivation (all *P*values \< 0.009). Reported levels of mental and social functioning were substantively different only between Class 3 and Class 5 (*P*values \< 0.003).

###### 

Descriptive data, disability, and fatigue scores (as medians) for each class defined in the five-class solution

  **Descriptive Data**           **Class-1**   **Class-2**   **Class-3**   **Class-4**   **Class-5**
  ------------------------------ ------------- ------------- ------------- ------------- -------------
  Number in class                **97**        **92**        **77**        **76**        **44**
                                                                                         
  Age (years)                    **42**        **44**        **48**        **51**        **38**
                                                                                         
  CFS illness duration (years)   **4.3**       **2.8**       **5.1**       **N/A**       **N/A**
                                                                                         
  **Disability (SF-36)**                                                                 
                                                                                         
  Physical Functioning           **80**        **70**        **85**        **93**        **100**
                                                                                         
  Mental Health                  **60**        **60**        **84**        **88**        **92**
                                                                                         
  Social Functioning             **75**        **56**        **100**       **100**       **100**
                                                                                         
  **Fatigue (MFI)**                                                                      
                                                                                         
  General Fatigue                **16**        **16**        **12**        **8**         **7**
                                                                                         
  Physical Fatigue               **12**        **14**        **11**        **7**         **6**
                                                                                         
  Mental Fatigue                 **13**        **13**        **8**         **7**         **5**
                                                                                         
  Reduced Activity               **9**         **11**        **7**         **6**         **6**
                                                                                         
  Reduced Motivation             **11**        **12**        **8**         **6**         **6**

SF-36 = Short-Form Health Survey

MFI = Multidimensional Fatigue Inventory

###### 

Independence of all five classes and the three classes defining ill/fatigued subjects

                           **All Classes**               **3 Ill Classes**   
  ------------------------ ----------------- ----------- ------------------- -----------
  **Disability (SF-36)**   **χ^2^**          ***P***     **χ^2^**            ***P***
                                                                             
  Physical functioning     **129.2**         **0.000**   **26.8**            **0.000**
                                                                             
  Mental health            **133.5**         **0.000**   **48.0**            **0.000**
                                                                             
  Social functioning       **159.1**         **0.000**   **57.1**            **0.000**
                                                                             
  **Fatigue (MFI)**                                                          
                                                                             
  General fatigue          **177.8**         **0.000**   **47.1**            **0.000**
                                                                             
  Physical fatigue         **149.2**         **0.000**   **22.7**            **0.000**
                                                                             
  Mental fatigue           **164.4**         **0.000**   **64.5**            **0.000**
                                                                             
  Activity reduction       **80.1**          **0.000**   **17.6**            **0.000**
                                                                             
  Motivation reduction     **117.4**         **0.000**   **30.2**            **0.000**

SF-36 = Short-Form Health Survey

MFI = Multidimensional Fatigue Inventory

Significant between-class differences also distinguished the three ill/fatigued classes in all disability and fatigue categories (Table [4](#T4){ref-type="table"}). Follow-up tests showed no significant differences between Classes 1 and 2 on the SF-36 dimensions \[[@B19]\] of mental functioning and the Multidimensional Fatigue Inventory subscales \[[@B20]\] of general fatigue, mental fatigue, and reduction in motivation (all *P*values \> 0.05). However, Class 2 reported significantly lower physical (*P*\< 0.000) and social functioning (*P*\< 0.01) and higher levels of physical fatigue (*P*\< 0.007) and activity reduction (*P*\< 0.009) than Class 1. Comparisons of SF-36 and fatigue scores between Classes 1 and 3 revealed no statistically significant difference in SF-36 physical functioning, but differences on the dimensions of mental and social functioning (both *P*values \< 0.000). Additional differences between these two classes were evident on general fatigue, mental fatigue, and reduction in motivation (all *P*values \< 0.000), and to a lesser degree for physical fatigue (*P*\< 0.01) and activity reduction (*P*\< 0.04). Comparisons between the most symptomatic Class 2 and the least symptomatic Class 3 of the ill classes were all significantly different at the P \< 0.000 level.

Table [5](#T5){ref-type="table"} shows the distribution of criterion-based diagnoses: CFS, unwell but not fatigued, and well individuals. People diagnosed as CFS fell almost exclusively into Classes 1 and 2. Those who were unwell but not fatigued were fairly evenly spread across all classes, while the well were most commonly found in Classes 4 and 5, with a small minority in Class 3.

###### 

Distribution of cases identified by the CDC research criteria for unexplained fatigue (CFS and unwell/not fatigued) and well controls across the empirically derived five classes: N (%)

  ----------------------------------------------------------------------------------------------------------
                                  **Class 1**\   **Class 2**\   **Class 3**\   **Class 4**\   **Class 5**\
                                  **(n = 97)**   **(n = 92)**   **(n = 77)**   **(n = 76)**   **(n = 44)**
  ------------------------------- -------------- -------------- -------------- -------------- --------------
  CFS (n = 92)                    41 (44)        47(51)         3(3)           1(1)           0

                                                                                              

  unwell not fatigued (n = 201)   53 (26)        43(21)         56(28)         32(16)         17(8)

                                                                                              

  well (n = 93)                   3 (3)          2(2)           18 (19)        43 (46)        27 (29)
  ----------------------------------------------------------------------------------------------------------

Table [6](#T6){ref-type="table"} compares and contrasts the four class solutions across the two studies in Georgia and Wichita. There was a close similarity in the content of all four classes. Table [7](#T7){ref-type="table"} compares and contrasts the five class solutions across the same two studies. Four out of the five classes were very similar in their content.

###### 

Comparisons of four class solutions across the two studies

  **Summarized content of classes**                               **Georgia Class (% cases)**   **Wichita Class (% cases)**
  --------------------------------------------------------------- ----------------------------- -----------------------------
  Not obese and well                                              1 (27)                        4 (16)
                                                                                                
  Not obese, polysymptomatic, depressed, insomnia                 2 (25)                        3 (26)
                                                                                                
  Obese, metabolic strain, polysymptomatic, insomnia, depressed   3 (25)                        1 (32)
                                                                                                
  Obese, metabolic strain, but relatively well                    4 (20)                        2 (28)

###### 

Comparisons of five class solutions across the two studies

  **Summarized content of classes**                                             **Georgia Class (% cases)**   **Wichita Class (% cases)**
  ----------------------------------------------------------------------------- ----------------------------- -----------------------------
  Not obese, polysymptomatic, depressed, insomnia                               1 (25)                        5 (13)
                                                                                                              
  Obese, metabolic strain, polysymptomatic, depressed, insomnia                 2 (24)                        1 (28)
                                                                                                              
  Obese, metabolic strain, fewer symptoms of pain and insomnia, not depressed   3 (20)                        2 (23)
                                                                                                              
  Not obese, fewer symptoms of pain and insomnia, not depressed                 4 (20)                        4 (17)
                                                                                                              
  Well, bar headache, young                                                     5 (11)                        
                                                                                                              
  Obese, metabolic strain, fewer symptoms of pain and insomnia, depressed                                     3 (19)

Discussion
==========

This analysis supported the heterogeneity of unexplained chronic fatigue in a population-derived sample. The most statistically rigorous latent classes were five in number, although the four-class solution was equally interpretable. The five-class solution provided three ill classes and two relatively well classes. The ill classes were differentiated by multiple symptoms, obesity, metabolic strain, depressed mood, and sleep problems. The four-class solution provided two well and two unwell groups, with differentiating variables being the same as for the five-class solution. The validation of the classes was supported by the significant differences across classes in the independent variables, such as fatigue subscale scores and disability. CFS was divided across two subgroups, while the unwell but not fatigued group was more heterogeneous, represented in all five classes. As expected, well people primarily made up Classes 4 and 5.

Comparison with the Wichita study
---------------------------------

How do these results compare with the Wichita classes? First, the main variables that differentiated the classes were similar: obesity, metabolic strain, multiplicity of physical symptoms, sleep problems, and depression. Secondly, the four-class solutions were very similar across the two studies, and four out of the five class solutions were also similar.

The dissimilarities include empirically describing a five-class solution in Georgia compared to a four-class solution in Wichita. The absence of measures of sympathetic nervous system arousal, such as nocturnal heart-rate variability and polysomnography, used in the Wichita study, may explain the lack of further similarities between the two samples. Similarly, the inability to differentiate a sixth class, similar to that reported in the Wichita sample, was probably related to the absence of the sex steroid hormone assays in the Georgian sample because the sixth class was defined primarily by being post-menopausal \[[@B12]\]. The SF-36 physical function subscale scores were higher than we expected, but the scores were similar to those of the relevant subjects from the Wichita study and probably reflect the sample being derived from the population rather than a clinic. Previous studies of CFS have also used a previous version (version 1 rather than 2) of the SF-36 scale, with a slightly different stem question, which also may have affected the data.

Comparisons with other studies of heterogeneity
-----------------------------------------------

The multiplicity of symptoms in some classes supports the two previous studies differentiating CFS on the basis of a minority having features of somatisation \[[@B8],[@B9]\]. The importance of depression reflects the differentiation found on the basis of mood disturbance in the largest study of heterogeneity using the Swedish twin registry, which found two main subgroups, one of which was differentiated primarily by comorbid mood disorders \[[@B25]\]. Kerr and colleagues\' finding of seven subgroups was based on secondary and tertiary care samples and was determined by gene expression alone \[[@B16]\]. Apart from the Wichita study, for which this is a replication, no other study has defined subgroups using both clinical and laboratory data, so no other comparisons are possible.

Limitations of this replication
-------------------------------

The most important limitation was the absence of some variables that had been used in the Wichita study. These primarily included objective measures of sleep, such as polysomnography, and autonomic nervous system tests such as heart rate variability. Our employment of proxy variables was unsuccessful because they rarely played a differentiating role in the analyses. We were careful to otherwise keep the variables and their preliminary processing, as well as the analyses, the same. In view of the discrepancy in important variables, it is remarkable that so many similarities were found. The addition of other variables, which neither study measured, such as actigraphy and other psychiatric comorbidities (e.g., anxiety), might have further enhanced the differentiation of classes \[[@B26]\]. As in all population surveys, there may have been a response bias of which we were not aware. Finally, this replication was based on American women, as in the Wichita study, so that these data cannot necessarily be generalized across other nations or to men.

Conclusion
==========

Implications of this replication
--------------------------------

What are the clinical implications of this work? This study\'s support for the heterogeneity of CFS, found in an independent population-derived sample, adds to the weight of evidence for the heterogeneous nature of CFS. We do not yet know whether this heterogeneity is important in determining response to different treatments, but future research studies should now examine for moderators of outcome that include obesity, metabolic syndrome, sleep problems, depression, and having multiple symptoms.

As in Wichita, these data suggest that the current research criteria for CFS, while useful in providing reliable findings across studies, do not constitute a homogeneous group of patients. The broadening of the concept of CFS to include patients with fewer symptoms but similar disability is supported by this replication \[[@B6],[@B7]\].

What are the research implications of this work? Future etiological work needs to take into account the heterogeneity of CFS, using the determining variables, such as obesity, multiple symptoms, and depression, to stratify samples. For instance, obesity leads to fatigue in multiple ways, including sleep disturbance, metabolic strain, increased inflammatory markers, and deconditioning \[[@B12],[@B27],[@B28]\]. This heterogeneity may well explain the dearth of replicated etiological findings in CFS. Addressing heterogeneity up front may help to determine the different etiologies and pathophysiologies that likely determine the different illnesses that make up CFS.
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